

Teresa Brophy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9127147/publications.pdf>

Version: 2024-02-01

18
papers

405
citations

759233

12
h-index

940533

16
g-index

18
all docs

18
docs citations

18
times ranked

697
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel role for the macrophage galactose-type lectin receptor in mediating von Willebrand factor clearance. <i>Blood</i> , 2018, 131, 911-916.	1.4	54
2	A novel role for von Willebrand factor in the pathogenesis of experimental cerebral malaria. <i>Blood</i> , 2016, 127, 1192-1201.	1.4	41
3	Redox properties of the tissue factor Cys186â€“Cys209 disulfide bond. <i>Biochemical Journal</i> , 2011, 437, 455-460.	3.7	34
4	Increased galactose expression and enhanced clearance in patients with low von Willebrand factor. <i>Blood</i> , 2019, 133, 1585-1596.	1.4	32
5	RN181, a novel ubiquitin E3 ligase that interacts with the KVGFFKR motif of platelet integrin Î±IIbÎ²3. <i>Biochemical and Biophysical Research Communications</i> , 2008, 369, 1088-1093.	2.1	31
6	N-linked glycans within the A2 domain of von Willebrand factor modulate macrophage-mediated clearance. <i>Blood</i> , 2016, 128, 1959-1968.	1.4	31
7	Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1â€“A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 845-855.	2.4	29
8	von Willebrand factor arginine 1205 substitution results in accelerated macrophageâ€“dependent clearance in vivo. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 821-826.	3.8	28
9	Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1200-1205.	3.8	27
10	N-linked glycan truncation causes enhanced clearance of plasma-derived von Willebrand factor. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2446-2457.	3.8	27
11	Identification of the Thiol Isomerase-binding Peptide, Mastoparan, as a Novel Inhibitor of Shear-induced Transforming Growth Factor Î²1 (TGF-Î²1) Activation. <i>Journal of Biological Chemistry</i> , 2013, 288, 10628-10639.	3.4	24
12	Galectin-1 and Galectin-3 Constitute Novel-Binding Partners for Factor VIII. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 855-863.	2.4	23
13	Marked elevation in plasma osteoprotegerin constitutes an early and consistent feature of cerebral malaria. <i>Thrombosis and Haemostasis</i> , 2016, 115, 773-780.	3.4	12
14	Investigating the clearance of VWF Aâ€“domains using siteâ€“directed PEGylation and novel Nâ€“linked glycosylation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1278-1290.	3.8	8
15	Hemostatic and protein C pathway dysfunction in the pathogenesis of experimental cerebral malaria. <i>Haematologica</i> , 2022, 107, 1950-1954.	3.5	3
16	N-Linked Glycans within the A1A2A3 Domains of VWF Play a Critical Role in Modulating Macrophage-Mediated Clearance. <i>Blood</i> , 2014, 124, 469-469.	1.4	1
17	Identification of Platelet Releasate Proteins that Bind to Mastoparan, a Peptide that Inhibits Shear-Induced TGF-Î²1 Activation,. <i>Blood</i> , 2011, 118, 3271-3271.	1.4	0
18	Identification Of Galectin-1 and Galectin-3 As Novel Binding Partners For Factor VIII. <i>Blood</i> , 2013, 122, 28-28.	1.4	0